Shin Lee’s Paper in Molecular Metabolism

The findings demonstrate that the activation of the hypothalamic pituitary adrenal axis (HPA) by the GLP-1 receptor agonist Exendin-4 (Ex-4) limits the eating-inhibitory properties of such treatments.

by Marcel Morf

The findings demonstrate that the activation of the hypothalamic pituitary adrenal axis (HPA) by the GLP-1 receptor agonist Exendin-4 (Ex-4) limits the eating-inhibitory properties of such treatments. Limiting endogenous glucocorticoid secretion and actions with low dose dexamethasone or lesions of the neural inputs that stimulate the HPA axis therefore enhances Ex-4’s potency to reduce food intake and body weight. Novel glucocorticoid receptor-based mechanisms may therefore help enhance GLP-1-based obesity therapies.

read the paper on external pagePubMed

JavaScript has been disabled in your browser